Edition:
United Kingdom

Cooper Companies Inc (COO.N)

COO.N on New York Stock Exchange

240.65USD
19 Jan 2018
Change (% chg)

$5.13 (+2.18%)
Prev Close
$235.52
Open
$235.82
Day's High
$241.54
Day's Low
$235.82
Volume
138,077
Avg. Vol
117,743
52-wk High
$256.27
52-wk Low
$179.41

Summary

Name Age Since Current Position

A. Thomas Bender

77 2007 Independent Chairman of the Board

Robert Weiss

70 2008 President, Chief Executive Officer, Non-Independent Director

Allan Rubenstein

72 2002 Independent Vice Chairman of the Board, Lead Director

Albert White

47 2016 Chief Financial Officer, Executive Vice President and Chief Strategy Officer

Paul Remmell

59 2012 President and Chief Executive Officer of CooperSurgical Inc.

Daniel McBride

52 2014 Chief Operating Officer, Executive Vice President; President of CooperVision, Inc.

Carol Kaufman

67 2013 Executive Vice President, Chief Administrative Officer, Secretary, Chief Governance Officer

Agostino Ricupati

2017 Chief Accounting Officer

Randal Golden

55 2014 Vice President, General Counsel

Kim Duncan

2015 Vice President -IR

Colleen Jay

54 2016 Independent Director

Michael Kalkstein

74 1992 Independent Director

William Kozy

64 2016 Independent Director

Jody Lindell

65 2006 Independent Director

Gary Petersmeyer

70 2013 Independent Director

Stanley Zinberg

82 1997 Independent Director

Biographies

Name Description

A. Thomas Bender

Mr. A. Thomas Bender is Independent Chairman of the Board of Cooper Companies Inc. Mr. Bender has served on our Board since 1994 and was elected Chairman in July 2002. He also served as our President and Chief Executive Officer from May 1995 until his retirement in October 2007. He previously served as President of CooperVision, our contact lens subsidiary, from June 1991 to December 2004. Between 1966 and June 1991, Mr. Bender held a variety of management positions at Allergan, Inc., a manufacturer of eye and skin care products, including Corporate Senior Vice President, and President and Chief Operating Officer of Herbert Laboratories, Allergan’s dermatology division. Mr. Bender serves on the board of directors of Allegro Ophthalmics LLC, a private ophthalmic company focused on pharmaceutical treatment of eye disease. Mr. Bender currently serves on the compensation and audit committees at Allegro. He also serves on the board of Mission Hospital Foundation in Mission Viejo, CA.

Robert Weiss

Mr. Robert S. Weiss is President, Chief Executive Officer, Non-Independent Director of the company. Mr. Weiss has served as our President since March 2008 and as our Chief Executive Officer since November 2007. He also served as President of CooperVision, our contact lens subsidiary, from March 2007 to February 2008. He previously served as our Chief Operating Officer from January 2005 to October 2007 and as Executive Vice President from October 1995 to October 2007. He served as our Chief Financial Officer from September 1989 to January 2005. He served as our Treasurer from 1989 to March 2002. Since joining us in 1977, he has held a number of finance positions both with us and Cooper Laboratories, Inc. (our former parent). Mr. Weiss is also a director of Accuray Incorporated (Nasdaq: ARAY), a company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. He serves on its nominating and governance committee and on its audit committee. He is also a member of the Board of Trustees of the University of Scranton in Pennsylvania and serves on its finance, advancement and audit committees.

Allan Rubenstein

Dr. Allan E. Rubenstein, M.D., is Independent Vice Chairman of the Board, Lead Director of Cooper Companies Inc. Dr. Rubenstein has served as our Vice Chairman and Lead Director since July 2002, and previously served as Chairman of the Board from July 1994 through July 2002. He served as Acting Chairman of the Board from April 1993 through June 1994. He is also Clinical Professor of Neurology and Pediatrics at New York University Langone Medical Center. Formerly, he was Chief Executive Officer of NexGenix Pharmaceuticals in NYC from 2003 to 2011. He currently serves as chairman of the board for Plex Pharmaceuticals (formerly CalAsia Pharmaceuticals) since September 2012. He is also a trustee of the Connecticut River Museum in Essex, Connecticut. Previously, he served as a director of BioClinica (NASDAQ: BIOC), a specialty clinical trials company, from 2000 to 2003. He is also Medical Director Emeritus of the Children’s Tumor Foundation and a consultant to the National Institutes of Health, the U.S. Food and Drug Administration and the U.S. Department of Defense, where he served as Chair of the Army Neurofibromatosis Research Program Integration Panel in 2001.

Albert White

Mr. Albert G. White, III, has been appointed as Chief Financial Officer, Executive Vice President and Chief Strategy Officer of Cooper Companies Inc, effective November 1, 2016. Mr. White has served as Chief Financial Officer since November 2016. He also serves as Executive Vice President and Chief Strategy Officer, positions he has held since December 2015 and July 2011, respectively. Since August 2015, Mr. White also oversees and directs our women’s healthcare business and is currently Chief Executive Officer of Cooper Medical, Inc., the parent company to CooperSurgical, Inc. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012. Prior to joining the Company, Mr. White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years.

Paul Remmell

Mr. Paul L. Remmell is President and Chief Executive Officer of the company, a subsidiary Company of Cooper Companies Inc. Mr. Remmell has been Chief Executive Officer of CooperSurgical, our women’s healthcare business, since January 2012, and has served as President of CooperSurgical since December 2004. He previously served as Chief Operating Officer of CooperSurgical from October 2000 to January 2012 and as Vice President of Finance from 1991 to December 2004.

Daniel McBride

Mr. Daniel G. McBride, Esq., has been Chief Operating Officer, Executive Vice President; President of CooperVision, Inc., of Cooper Companies Inc. Mr. McBride has served as Executive Vice President and Chief Operating Officer since November 2013 and as the President of CooperVision, our contact lens subsidiary since February 2014. He previously served as our Chief Risk Officer from July 2011 through October 2013, as our General Counsel from November 2007 through January 2014, and as Vice President from July 2006 through October 2013. He also served as Senior Counsel from February 2005 through November 2007. Prior to joining Cooper, Mr. McBride was an attorney with Latham & Watkins LLP from October 1998 to February 2005, concentrating on mergers and acquisitions and corporate finance matters.

Carol Kaufman

Ms. Carol R. Kaufman is Executive Vice President, Chief Administrative Officer, Secretary, Chief Governance Officer of Cooper Companies Inc. She previously served as Senior Vice President of Legal Affairs from December 2004 to July 2012. She has also served as Vice President and Chief Administrative Officer since October 1995 and as Vice President of Legal Affairs and Secretary since March 1996. From January 1989 through September 1995, she served as Vice President, Secretary and Chief Administrative Officer of Cooper Development Company, a healthcare and consumer products company. She previously held a variety of financial positions with Cooper Laboratories, Inc. (our former parent) since joining that company in 1971. Ms. Kaufman currently serves as a director for Insperity, Inc. (NYSE: NSP), a publicly traded provider of human resources outsourcing options, and is a member of its finance, risk management and audit committee. She formerly served as a director of Chindex International, Inc. (NASDAQ: CHDX) and as a member of its audit and compensation committees and chaired the nominating and corporate governance committees. She also served as a member of the Special Transaction Committee in connection with sale of Chindex to TPG in 2014.

Agostino Ricupati

Mr. Agostino Ricupati is Chief Accounting Officer of the company. He was appointed to in July 2017. Mr. Ricupati previously served as Vice President, Tax for the Company from July 2013 to July 2017. Prior to joining Cooper, he served as International Tax Director for Intel Corp. (NASDAQ: INTC) from 2010 to 2013 and in various other senior finance and tax positions over the past 20 years. He holds a master degree from DePaul University and is a Certified Public Accountant.

Randal Golden

Mr. Randal L. Golden, Esq., is a Vice President, General Counsel of Cooper Companies, Inc., He previously served as our Assistant General Counsel from May 2013 through January 2014. He also served as senior counsel from March 2010, when he joined the Company, until May 2013. Prior to joining Cooper, he served as Senior Director & Legal Counsel at Align Technology, Inc. from 2005 through 2010 and as Director of Legal Affairs & Senior Counsel with Nokia, Inc. from 2000 to 2005. Mr. Golden also held various associate and senior legal positions prior to 2000, focusing on litigation and commercial and business law.

Kim Duncan

Colleen Jay

Ms. Colleen E. Jay is Independent Director of the Company. s. Jay currently serves as a Loaned Senior Executive for Catalyst, Inc., a non-profit organization dedicated to improving workplace inclusion for women. In this role, she is considered to be “on loan” from her service at Procter & Gamble (NYSE: PG), an American multinational consumer goods company. Until taking the Loaned Executive role at Catalyst in October 2016, Ms. Jay served as President of the Beauty Specialty Business at Procter & Gamble from 2015 and was responsible for the Wella Professional Salon, Cosmetics, Retail Hair Color and Fragrance businesses. Prior to taking leadership of the Beauty Specialty Business, Ms. Jay led the Global Retail Hair Care and Color division of Procter & Gamble from 2012 to 2015 and the Global Female Beauty division from 2010 to 2012. She also served as Vice President & General Manager, Greater China Feminine Care, Personal Cleansing, Oral Care & Entire China Marketing Function from 2006 to 2009, where she was responsible for businesses with a combined value of over $1 billion. She has worked in various positions with Procter & Gamble since July 1985 and has led operational units in the United States, Canada, China and Switzerland (including leading global businesses) during the course of her career.

Michael Kalkstein

Mr. Michael H. Kalkstein is Independent Director of Cooper Companies Inc. Mr. Kalkstein was a partner at Dechert LLP, an international law firm, from June 2003 through June 2007 and was Co-chair of the firm’s Intellectual Property Practice Group. He also served as the Managing Partner of Dechert’s Palo Alto office from June 2003 through December 2005. As of June 30, 2007, he has retired from active practice and continues to be “Of Counsel” to Dechert at its Mountain View, CA office. Previously, from September 1999 through May 2003, he was a partner at Oppenheimer, Wolff & Donnelly, LLP, an international law firm, and a member of its Policy and Technologies Committees. Mr. Kalkstein currently serves as a director on the board of the Merola Opera Program, a non-profit arts organization affiliated with the San Francisco Opera, and sits on its finance and Medallion Society committees. He also served as a member of the Board of Trustees of Opera San Jose from 1984 to October 2010, serving as its President from 1992 to 1994. He was a member of the Alliance of CEOs from 2001 to June 2007 and was a member of the board of directors of the Law Foundation of Silicon Valley from 2002 to June 2007. Until January 2007, he also served as a director of the Northern California Chapter of the National Association of Corporate Directors.

William Kozy

Mr. William A. Kozy is Independent Director of the Company. Mr. Kozy served as the Chief Operating Officer of Becton Dickinson (NYSE: BDX) from 2012 until his retirement in 2016 and as its Executive Vice President from 2006 until 2016. He also served as a member of the corporate Leadership Team for Becton Dickinson and in various executive roles since 1988, including senior vice president of company operations from 1998 until 2002, president of BD Diagnostics from 2002 through 2006, president of the BD Biosciences segment from 2006 to 2009 and head of BD Medical from 2009 through 2011. He continues as an active emeritus senior faculty member of the Center for Becton Dickinson Leadership, engaged in Leadership Development for the company. Mr. Kozy is a member of the Hackensack Meridian Health Board of Governors where he serves on the Strategic Planning and Executive Compensation Committees. He also serves on the Board of the Franciscan Sisters of the Poor Foundation. He is an active benefactor and volunteer for the Karen Ann Quinlan Hospice organization, and the Immokalee Child Care Center (Naples, Florida).

Jody Lindell

Ms. Jody S. Lindell is Independent Director of Cooper Companies Inc. Ms. Lindell is President and Chief Executive Officer of S.G. Management, Inc., an asset management company she has headed since 2000. Until May 2000, Ms. Lindell was a partner with KPMG LLP where she served as Partner-In-Charge of the Industrial Markets and Healthcare and Life Sciences practices for the Western Area. Ms. Lindell is also a Certified Public Accountant (inactive). Through September 2007, she served as a director and on the audit and director’s loan committees for First Republic Bank, a publicly traded financial institution. First Republic Bank was acquired in 2007, underwent a management led buyout in mid-2010 and again became publicly traded (NYSE: FRC) in December 2010. Ms. Lindell continues to serve as a director, chairs the audit committee and serves on the director’s loan committee for First Republic Bank. She also currently serves on the board of directors and the audit and nominating and corporate governance committees of PDL BioPharma (NasdaqGS: PDLI).

Gary Petersmeyer

Mr. Gary S. Petersmeyer is Independent Director of Cooper Companies Inc. Mr. Petersmeyer currently serves as a consultant to companies in the pharmaceutical and medical device industries. Most recently he co-founded Aesthetic Sciences Corporation in 2004 and served as the Chief Executive Officer and Chairman until December 2010. Prior to that he served as President and Chief Operating Officer of Pherin Pharmaceuticals, Inc. from 2000 to 2001 and as President and Chief Operating Officer of Collagen Corporation, Inc. from 1995 to 2000. From 1976 to 2000 he served in various management positions for pharmaceutical and medical device companies. Mr. Petersmeyer serves as a director and member of the compensation and audit committees of Omnicell, Inc. (NASDAQ: OMCL). He also served as director and chairman of the board of Cardica, Inc. (NASDAQ: CRDC) through November 2015. He has previously served on the boards of Visx Incorporated and Roxro Pharmaceuticals prior to their acquisitions. He also serves as chairman of the board for Positive Coaching Alliance, a non-profit organization dedicated to improving youth sports.

Stanley Zinberg

Dr. Stanley Zinberg, M.D., is Independent Director of Cooper Companies Inc. Dr. Zinberg is a retired obstetrician-gynecologist who served as Deputy Executive Vice President and Vice President of Practice Activities for the American College of Obstetricians and Gynecologists (ACOG) in Washington, D.C. from 1993 through his retirement in December 2007. From 1981 until 1993 he served as Chief, Obstetrics and Gynecology, and Director, OB-GYN Residency Program at NY Downtown Hospital, where from 1990 through 1992 he also served as President of the Medical Staff and was a member of the Board of Trustees until June 2013. He is certified by the American Board of Obstetrics and Gynecology and is a member of the faculty of the Departments of Obstetrics and Gynecology at New York University School of Medicine, the Cornell University College of Medicine and the Georgetown University School of Medicine. He is the author of numerous editorials, scientific papers and book chapters in the field of women’s healthcare. In addition, Dr. Zinberg obtained a Master’s Degree in Health Administration, with an emphasis on not-for-profit finance, in 1990 from the Graduate School of Public Administration of New York University. Currently, Dr. Zinberg is a director on the Peconic Bay Medical Center board and serves on its finance committee, investment committee, and compensation committee. He is also a director on the Peconic Bay Medical Center Foundation board. He is also President-Elect of the American Gynecologic Club and will assume the presidency in 2017. Additionally, he serves as a director and chairman of the board of the Westhampton Beach Performing Arts Center, as a member of the Southampton Town Board of Ethics in Southampton, NY, and as a member of the boards of overseers of Northwell Health.

Basic Compensation

Name Fiscal Year Total

A. Thomas Bender

492,039

Robert Weiss

6,508,600

Allan Rubenstein

381,440

Albert White

3,418,900

Paul Remmell

1,166,760

Daniel McBride

3,711,710

Carol Kaufman

2,232,230

Agostino Ricupati

--

Randal Golden

--

Kim Duncan

--

Colleen Jay

197,064

Michael Kalkstein

363,950

William Kozy

197,064

Jody Lindell

389,825

Gary Petersmeyer

373,450

Stanley Zinberg

363,950
As Of  31 Oct 2016